American Chemical Society
Browse
bc0c00202_si_001.pdf (2 MB)

Synthesis and Evaluation of New Trivalent Ligands for Hepatocyte Targeting via the Asialoglycoprotein Receptor

Download (2 MB)
journal contribution
posted on 2020-05-09, 16:04 authored by Galina S. Reshitko, Emil Yu. Yamansarov, Sergei A. Evteev, Elena V. Lopatukhina, Dmitry O. Shkil’, Irina V. Saltykova, Anton V. Lopukhov, Sergey V. Kovalev, Alexander N. Lobov, Ivan V. Kislyakov, Olga Yu. Burenina, Natalia L. Klyachko, Anastasiia S. Garanina, Olga A. Dontsova, Yan A. Ivanenkov, Alexander S. Erofeev, Peter V. Gorelkin, Elena K. Beloglazkina, Alexander G. Majouga
Since the asialoglycoprotein receptor (also known as the “Ashwell–Morell receptor” or ASGPR) was discovered as the first cellular mammalian lectin, numerous drug delivery systems have been developed and several gene delivery systems associated with multivalent ligands for liver disease targeting are undergoing clinical trials. The success of these systems has facilitated the further study of new ligands with comparable or higher affinity and less synthetic complexity. Herein, we designed two novel trivalent ligands based on the esterification of tris­(hydroxymethyl) aminomethane (TRIS) followed by the azide–alkyne Huisgen cycloaddition with azido N-acetyl-d-galactosamine. The presented triazolyl glycoconjugates exhibited good binding to ASGPR, which was predicted using in silico molecular docking and assessed by a surface plasmon resonance (SPR) technique. Moreover, we demonstrated the low level of in vitro cytotoxicity, as well as the optimal spatial geometry and the required amphiphilic balance, for new, easily accessible ligands. The conjugate of a new ligand with Cy5 dye exhibited selective penetration into HepG2 cells in contrast to the ASGPR-negative PC3 cell line.

History